Flush with cash, Novo Nordisk Foundation now plans to reinvest some GLP-1 profits into regenerative medicines
The Novo Nordisk Foundation, the majority owner of Novo Nordisk, plans to put more money into regenerative medicines, including stem cells and cell therapies for